Skip to main content

Deepak R Jadon

Dr Deepak Jadon is a consultant rheumatologist, Director of the Rheumatology Research Unit, and lead for psoriatic arthritis (PsA) at Addenbrooke’s Hospital, Cambridge, UK. Having grown up in Cardiff, he graduated from the University of Wales College of Medicine, Cardiff, in 2003, and then undertook clinical training in rheumatology and general internal medicine in Bath and Bristol from 2007 to 2015. He completed his PhD thesis on biomarkers of PsA phenotypes at the Royal National Hospital for Rheumatic Diseases, Bath, UK, in 2015.

Dr Jadon has particular expertise in the investigation and management of PsA, ankylosing spondylitis (AS), spondyloarthritis (SpA), and rheumatoid arthritis (RA). He is qualified in the use of musculoskeletal ultrasound and as part of a team, will be using it to improve diagnostic accuracy and assessment of disease activity.

His research interests include genetic and serum biomarkers of PsA, AS, and SpA, in particular those that predict prognosis and developing psoriatic spondyloarthropathy or arthritis mutilans. He has also researched the clinical and radiographic differences between PsA and AS, and juvenile- versus adult-onset AS. As Director of the Rheumatology Research Unit, he leads on phase IIa–IV clinical studies of novel therapeutic agents for PsA, AS, SpA, and RA.

10-07-2019 | Psoriatic arthritis | Highlight | Article

Methotrexate versus etanercept as first-line therapy for psoriatic arthritis

William Tillett, Deepak Jadon, and Jobie Evans debate the clinical reasons relating to the efficacy, safety, and practicality of using etanercept or methotrexate as first-line therapy for psoriatic arthritis.

Image Credits